Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...

This year, 18 presenters will deliver named lectures during the American Academy of Ophthalmology meeting. Lee M. Jampol, MD, will deliver the lecture “How to Describe New Diseases, the Same Skills ...

Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5 ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and ...

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

Peter Kaiser, MD, from Ocular Therapeutix, introduces OTX-TKI (Axpaxli), a novel tyrosine kinase inhibitor delivered through a proprietary hydrogel platform. This innovative treatment for wet ...

Patricio Schlottmann, MD | Authors | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

The American Academy of Ophthalmology (AAO) annual meeting and expo are fast approaching on October 18 and will run through October 20 at the Orange County Convention Center West in Orlando. In a ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...